Post-earnings recap
Reported
Thu, Oct 28, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a wider-than-expected loss per share, which contributed to a significant drop in stock price. The lack of revenue figures and guidance left investors uncertain about the company's future performance. The stock's 15.18% decline reflects market disappointment and concerns about the company's current trajectory.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.51 | N/A | -0.07% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current market conditions and their impact on performance. They highlighted a focus on long-term strategies despite short-term setbacks.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
Future strategies were discussed, but no specific guidance was provided.